相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells
Harunori Nakashima et al.
MOLECULAR CARCINOGENESIS (2012)
Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters
Junlin Li et al.
BMC CANCER (2011)
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
H. Zhang et al.
ONCOGENE (2011)
TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1
H-O Jin et al.
ONCOGENE (2011)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
Somatic mutations of signaling genes in non-small-cell lung cancer
Heather R. Sanders et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer
Roelof Koster et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Acquired Activation of the Akt/Cyclooxygenase-2/Mcl-1 Pathway Renders Lung Cancer Cells Resistant to Apoptosis
Wenjie Chen et al.
MOLECULAR PHARMACOLOGY (2010)
Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells
Y. Gan et al.
ONCOGENE (2010)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway
Wen-Lei Zhuo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Regulation of cancer cell survival, migration, and invasion by twist: AKT2 comes to interplay
George Z. Cheng et al.
CANCER RESEARCH (2008)
Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins
Medhi Wangpaichitr et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
mTORC1 promotes survival through translational control of Mcl-1
John R. Mills et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
Hector Peinado et al.
NATURE REVIEWS CANCER (2007)
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
Guo Wei et al.
CANCER CELL (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
mTOR signaling: implications for cancer and anticancer therapy
E Petroulakis et al.
BRITISH JOURNAL OF CANCER (2006)
Regulation of cap-dependent translation by eIF4E inhibitory proteins
JD Richter et al.
NATURE (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells
XH Wang et al.
ONCOGENE (2004)
Epithelial-mesenchymal transitions:: Twist in development and metastasis
YB Kang et al.
CELL (2004)
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
J Yang et al.
CELL (2004)
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
S Chan
BRITISH JOURNAL OF CANCER (2004)
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
D Nijhawan et al.
GENES & DEVELOPMENT (2003)
Epithelial-mesenchymal transitions in tumour progression
JP Thiery
NATURE REVIEWS CANCER (2002)
分享论文
